Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Delay Delay Delay

<< Previous

Bullboard Posts

Next >>

Comment by Speyeder999on Feb 08, 2023 11:36am

185 Views

Post# 35274561

RE:Delay Delay Delay

You are too kind goldtech.

Over ''a year late'' is an understatement, more like 3 and counting. Perhaps they are using another calender besides the Gregorian version we all adhere to (lol)?. In all fairness, lack of funds and the COVID pandemic definitely altered their plans and hopefully things will start moving soon.

Although, it did seem to get a little quiet on the news front since last fall. They even stopped posting weekly updates on their Facebook page, guess the (person posting) contract expired!

ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer's Disease

T.PMN | June 12, 2018

Canada NewsWire

TORONTO and CAMBRIDGE, MA, June 12, 2018

Program is on track for clinical trial start in H2 2019

https://stockhouse.com/news/press-releases/2018/06/12/promis-neurosciences-initiates-manufacturing-of-pmn310-its-lead-therapeutic